Trial Profile

A Double-blind, Placebo-controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Administration of XEN1101 in Healthy Male Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Sep 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Sep 2018 Status changed from active, no longer recruiting to completed, according to a Xenon Pharmaceuticals media release.
29 Aug 2018 According to a Xenon Pharmaceuticals media release, lead investigator, Dr. Isabella Premoli of this XEN1101 phase 1b TMS study will be presenting the results in a podium presentation at the 13th European Congress on Epileptology held in Vienna, Austria today.
29 Aug 2018 Results of this phase Ib, cross-over TMS study presented in a Xenon Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com